Brokers Offer Predictions for Gossamer Bio FY2026 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS) – Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Gossamer Bio in a report issued on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer forecasts that the company will post earnings of ($0.45) per share for the year. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share.

Other analysts have also issued research reports about the company. Wedbush reissued an “outperform” rating and set a $4.00 price objective on shares of Gossamer Bio in a report on Friday, May 16th. The Goldman Sachs Group lifted their target price on shares of Gossamer Bio from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, May 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Gossamer Bio in a research report on Tuesday, March 18th.

Gossamer Bio Stock Down 6.0%

Shares of GOSS opened at $1.25 on Tuesday. Gossamer Bio has a 52 week low of $0.51 and a 52 week high of $1.55. The firm has a market capitalization of $284.13 million, a P/E ratio of -3.91 and a beta of 1.85. The company has a 50-day simple moving average of $1.03 and a 200-day simple moving average of $1.04. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02. The company had revenue of $9.89 million for the quarter, compared to analyst estimates of $3.95 million.

Institutional Trading of Gossamer Bio

Large investors have recently added to or reduced their stakes in the company. Octagon Capital Advisors LP raised its stake in shares of Gossamer Bio by 99.7% in the fourth quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock valued at $16,599,000 after acquiring an additional 9,162,117 shares during the last quarter. Alyeska Investment Group L.P. increased its holdings in shares of Gossamer Bio by 52.7% in the fourth quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company’s stock worth $7,968,000 after acquiring an additional 3,041,058 shares in the last quarter. Monaco Asset Management SAM raised its stake in shares of Gossamer Bio by 39.5% in the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock valued at $4,859,000 after purchasing an additional 1,520,721 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Gossamer Bio by 24.6% in the 1st quarter. Acadian Asset Management LLC now owns 6,358,113 shares of the company’s stock valued at $6,991,000 after acquiring an additional 1,253,353 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Gossamer Bio by 720.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company’s stock worth $1,034,000 after purchasing an additional 825,047 shares in the last quarter. 81.23% of the stock is owned by institutional investors.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.